PT - JOURNAL ARTICLE AU - Umair, Massab AU - Ikram, Aamer AU - Rehman, Zaira AU - Haider, Adnan AU - Badar, Nazish AU - Ammar, Muhammad AU - Ahad, Abdul AU - Suleman, Rana AU - Salman, Muhammad TI - Genomic diversity of SARS-CoV-2 in Pakistan during fourth wave of pandemic AID - 10.1101/2021.09.30.21264343 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.30.21264343 4099 - http://medrxiv.org/content/early/2021/10/03/2021.09.30.21264343.short 4100 - http://medrxiv.org/content/early/2021/10/03/2021.09.30.21264343.full AB - The emergence of different variants of concern of SARS-CoV-2 has resulted in upsurges of COVID positive cases around the globe. Pakistan is also experiencing fourth wave of COVID-19 with increasing number of positive cases. In order to understand the genomic diversity of circulating SARS-CoV-2 strains during fourth wave of pandemic in Pakistan, the current study was designed. The samples from 89 COVID-19 positive patients were subjected to whole genome sequencing using GeneStudio S5. The results showed that 99% (n=88) of isolates belonged to delta variant and only one isolate belonged to alpha variant. Among delta variant cases 26.1% (n=23) isolates were showing B.1.617.2 while 74% of isolates showing AY.4 lineage. Islamabad was found to be the most affected city with 54% (n=48) of cases, followed by Karachi (28%, n=25), and Rawalpindi (10%, n=9). AY.4 has slight difference in mutation profile compared to B.1.617.2. E156del, G142D and V26I mutations in spike and T181I in NSP6 were present in B.1.617.2 but not in AY.4. Interestingly, A446V mutation in NSP4 has been only observed in AY.4. The current study highlights the circulation of primarily delta variant (B.1.617.2 and AY.4) during fourth wave of pandemic in Pakistan.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding received for the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by ethical review committee of National Institute of Health.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the sequences generated in the current study are submitted to the GISAID that are available at https://www.gisaid.org/login/ under the accession numbers: EPI_ISL_3462498- EPI_ISL_3462527, EPI_ISL_3553499-EPI_ISL_3553528, EPI_ISL_3827529-EPI_ISL_3827557.